2007年の製薬産業動向‐教訓

SPECIAL REPORT: 2007 Industry Dynamics - Lessons Learned

発行	Decision Resources, Inc.
出版日	2007年12月	商品コード	58744
ページ情報	英文 39 Pages
価格	こちらの商品の販売は終了いたしました。

概要
原文目次
関連レポート

当商品の販売は、2011年12月21日を持ちまして終了しました。

原文目次

Abstract

Introduction

Moderate successes and "business as usual" characterize the performance of the pharmaceutical industry in 2007. In this year-end retrospective report, we contemplate the importance of key events and achievements in the industry. We asked industry-leading experts to identify particularly noteworthy events in 2007 and lessons that can be learned for 2008. Six themes emerged; our experts discuss their implications for the industry. Furthermore, we offer a Spectrum Scorecard that assesses industry performance in a variety of critical areas.

Get the Answers You Need to Shape Your Strategy

The pharmaceutical industry may never be to return to its glory days, but it can exert control over its future through the strategies and changes that it is willing to adopt today. What strategic options are essential to achieve success in today' s evolving markets? What are the future implications of these changes for pharmaceutical companies?
Pharmaceutical companies must ensure they are "fi t for purpose" in today' s business environment. What strategies can pharmaceutical management pursue to capture and harness the essence of a resultsoriented business and make their companies truly fi t for purpose? How can they uncover previously unrealizable profi ts and growth and also differentiate themselves so that they can grasp valuable competitive advantage?

Scope

2007 in review: a retrospective on news and key themes from the year.
Seeking a new vision for the pharmaceutical industry: looking for the Holy Grail of opportunity.
Negative industry impacts: from generics erosion, biogenerics, declining productivity, and drug safety concerns combined with the increased importance of specialty pharma and biotech.
New strategies needed for future success: rethinking the blockbuster strategy, a holistic approach to management style, fi t with strategy, choosing strategies and opportunities wisely.
Jumping on technology opportunities: identifying key technologies and turning innovation into new products and services.
New value propositions: value-for-money.
Growing infl uence of U.S. states: legislative bills, litigation by state attorneys general, lessons learned.
2007 industry report card: how successful was Big Pharma in capitalizing on the many opportunities available in 2007?

Executive Summary
- Strategic Considerations
- Stakeholder Implications
2007 in Review
Looking for the Grail
Noteworthy 2007 News and Events That Signifi cantly Impact the Pharmaceutical Industry
- 2007' s Problems with Drug Safety
- Big Pharma' s Ongoing Productivity Problems
- Ramifi cations of Biogenerics Entering the Marketplace
- Ramifi cations of Patent Expiries
- Ascendancy of Specialty Pharma and Biotech
Retrenching and Choosing Wisely
- Blockbuster Numbers Creep Upward, but Growth Grinds Almost to a Halt
- Executing Change Requires a Holistic Approach to Managing a Company
- A Tale of Two Management Styles: Pfi zer Versus Schering-Plough
  - Management Style
  - Insights from the Asenapine Story
  - Lessons to Be Learned About Management
- Choosing Wisely Has Never Been More Important
Jumping on Technology Opportunities
- The Quest for Innovation: Valuable Technology Opportunities, Circa 2007
- Future Lifeblood of the Pharmaceutical Industry
New Value Propositions: Value-for-Money
Increasing Power of Activist States
- 2007 Lessons to Be Learned
- 2007 State Legislative Bills
- State Attorneys General Not Afraid to Litigate
2007 Spectrum Scorecard
Showcase of Decision Resources, Inc., Reports and Presentations